Patients treated with belatacept (Nulojix, Bristol-Myers-Squibb) are at increased risk of developing 2 potentially fatal complications: post-transplant lymphoproliferative disorder (PTLD), which predominantly involves the central nervous system, and progressive multifocal leukoencephalopathy, according to a recent FDA Safety Alert. The risk of PTLD is higher for transplant patients who have never been exposed to Epstein-Barr virus (EBV) and therefore is indicated for use only in transplant patients who are EBV seropositive.
FDA has approved the Risk Evaluation and Mitigation Strategy (REMS) for Fentora (fentanyl buccal tablet) [C-II] and Actiq (oral transmucosal fentanyl citrate) [C-II]. Both products, manufactured by Cephalon, are indicated for management of breakthrough pain in opioid-tolerant patients with cancer.
FDA has approved ticagrelor (Brilinta, AstraZeneca) tablets to reduce the rate of heart attack and cardiovascular death in adult patients with acute coronary syndrome.
An increase in methicillin-resistant Staphylococcus aureus (MRSA) has led to a significant increase in cases of children?s pneumonia, a new study has reported.
FDA has approved the influenza vaccine formulation for the 2011-2012 vaccine that will be used by the 6 manufacturers licensed to produce and distribute influenza vaccine for the United States.
The CDC is concerned about the increasing potential in gonorrhea patients for resistance to cephalosporin.
Experts suggest that pharmacogenomics and personalized medicine may soon change the practice of community pharmacy.
Chronic cluster headaches are debilitating for patients who experience them. A recent study concluded that low-intensity anticoagulation with warfarin was associated with significantly higher incidence of remission and less headache impact on patients' lives.
Hospitals and health systems that have not caught up with the latest version of The Joint Commission's National Patient Safety Goals could run into trouble.
According to new guidelines, researchers at the Alzheimer's Association and the National Institute of Aging of the National Institutes of Health have categorized AD into 3 different stages: preclinical, mild cognitive impairment, and Alzheimer's dementia.